New Medicare Part B Payment Model is Most Recent Payor Response to Increasing Drug Prices

By Lee H. Rosebush and Nita Garg on April 20, 2016 Posted in Uncategorized

Recent activity by the federal government along with commercial payors may be indicative of further changes to how payors, providers, and pharmaceutical manufacturers engage in prescription drug arrangements. A recently announced proposed rule by CMS would create a new Medicare Part B prescription drug payment model intended to improve quality of care and deliver better value for … Continue Reading

CMS Pitches Controversial Payment Model for Medicare Part B Drugs

By Lee H. Rosebush and Nita Garg on March 25, 2016 Posted in Uncategorized

CMS recently announced a proposed rule that would potentially create a new Medicare Part B prescription drug payment model. The proposed model is intended to improve quality of care and deliver better value for Medicare Part B beneficiaries. However, many providers and drug manufacturers have expressed concern that the new payment model will emphasize cost-cutting measures at … Continue Reading

Hello Budget Agreement; Goodbye Provider-Based Status?

By Robert M. Wolin, Susan Feigin Harris and Lee H. Rosebush on November 6, 2015 Posted in Uncategorized

H.R. 1314, the Bipartisan Budget Act of 2015, was signed into law by President Obama on November 2, 2015. The two-year budget framework, which raises the federal debt limit through March 2017, partially rolls back the Budget Control Act’s discretionary caps by $80 billion above the sequester level for two consecutive years (FY 2016 and … Continue Reading